Home
HelpTest Code ROGM Measles (Rubeola) Virus Antibody, IgM and IgG, Serum
Reporting Name
Measles (Rubeola) Ab, IgM and IgG,SUseful For
Diagnosing measles virus infection
Determination of immune status of individuals to the measles virus using IgG antibody testing
Documentation of previous infection with measles virus in an individual without a previous record of immunization to measles virus
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ROM | Measles (Rubeola) Ab, IgM, S | Yes | Yes |
| ROPG | Measles (Rubeola) Ab, IgG, S | Yes | Yes |
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SerumSpecimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.6 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 14 days | |
| Frozen | 14 days |
Reference Values
IMMUNOGLOBULIN M
Negative
Reference values apply to all ages.
IMMUNOGLOBULIN G
Vaccinated: positive (≥1.1 AI)
Unvaccinated: negative (≤0.8 AI)
Reference values apply to all ages.
Day(s) Performed
Monday through Saturday
CPT Code Information
86765-Rubeola IgM
86765-Rubeola IgG
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| ROGM | Measles (Rubeola) Ab, IgM and IgG,S | 90253-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 80979 | Measles (Rubeola) Ab, IgM, S | 35276-5 |
| ROG | Measles (Rubeola) Ab, IgG, S | 35275-7 |
| DEXG3 | Measles IgG Antibody Index | 5244-9 |
Clinical Information
The measles virus is a member of the Paramyxoviridae family of viruses, which include parainfluenza virus serotypes 1-4, mumps, respiratory syncytial virus (RSV), and metapneumovirus. The measles virus is one of the most highly contagious infectious diseases among unvaccinated individuals and is transmitted through direct contact with aerosolized droplets or other respiratory secretions from infected individuals. Measles has an incubation period of approximately 8 to 12 days, which is followed by a prodromal phase of high fever, cough, coryza, conjunctivitis, and malaise. Koplik spots may also be apparent on the buccal mucosa and can last for 12 to 72 hours.(1,2) Following this phase, a maculopapular, erythematous rash develops beginning behind the ears and on the forehead and spreading centrifugally to involve the trunk and extremities.
Immunocompromised individuals, pregnant women, and those with nutritional deficiencies, are particularly at risk for serious complications following measles infection, which include pneumonia and central nervous system involvement.(1,3)
Following implementation of the national measles vaccination program in 1963, the incidence of measles infection has fallen to below 0.5 cases per 1,000,000 population and the virus is no longer considered endemic in the United States.(4) Measles outbreaks continue to occur in the United States, however, due to exposure of nonimmune individuals or those with waning immunity to infected travelers. The measles outbreak in 2011 throughout Western Europe emphasizes the persistence of the virus in the worldwide population and the continued need for national vaccination programs.(5)
The diagnosis of measles infection is often based on clinical presentation alone. The presence of IgM-class antibodies suggests recent infection but should not be used alone to diagnose measles infection. Screening for IgG-class antibodies to measles virus aids in identifying nonimmune individuals.
Interpretation
This assay tests for both IgM and IgG-class antibodies. The presence of IgM-class antibodies, with or without the presence of IgG-class antibodies, to measles virus may support a clinical diagnosis of recent/acute phase infection with the virus. IgM results alone should not be used to diagnose measles virus infection.
The absence of IgM-class antibodies suggests lack of an acute phase infection with measles virus. However, serology may be negative for IgM-class antibodies in early disease, and results should be interpreted in the context of clinical findings.
Testing for IgM-class antibodies to measles should be limited to patients with clinically compatible disease.
The presence of detectable IgG-class antibodies, in the absence of IgM-class antibodies, indicates prior exposure to the measles virus through infection or immunization. These individuals are considered immune to measles infection.
The absence of detectable IgG-class antibodies suggests the lack of a specific immune response to immunization or no prior exposure to the measles virus. These individuals are considered nonimmune to measles virus infection.
Cautions
A serum specimen collected during the acute phase of infection or soon after vaccination may yield negative for IgM- or IgG-class antibodies.
Rare heterotypic IgM responses to measles virus have been reported in patients with rubella virus, chronic active hepatitis, systemic lupus, and infectious mononucleosis.(6)
IgG-class antibodies to measles virus may be present in serum specimens from individuals who have received blood products within the past several months, but who have not been immunized or have experienced past infection with this virus.
Supportive Data
Immunoglobulin G:
To evaluate the accuracy of the BioPlex Measles IgG multiplex flow immunoassay (MFI), 500 prospective serum samples were analyzed in a blinded fashion by the Diamedix Measles IgG enzyme immunoassay (EIA) and the BioPlex Measles IgG assay. Samples with discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further discrepancies were evaluated by the SeraQuest Measles IgG EIA . The results are summarized in the table below:
Table: Diamedix measles IgG EIA
|
BioPlex measles IgG |
|
Positive |
Negative |
Equivocal |
|
Positive |
420 |
1(a) |
0 |
|
|
Negative |
10(b) |
27 |
17 |
|
|
Equivocal |
14 |
0 |
11 |
(a) This sample tested negative by the SeraQuest Measles IgG EIA
(b) All 10 samples tested positive by the SeraQuest Measles IgG EIA
Sensitivity: 94.6% (420/444); 95% CI: 92.1%-96.4%
Specificity: 96.4% (27/28); 95% CI: 80.8%-100.0%
Overall Percent Agreement: 91.6% (458/500); 95% CI: 88.8%-93.8%
Clinical Reference
1. Perry RT, Halsey NA: The clinical significance of measles-a review. J Infect Dis. 2004 May 1;189 Supp 1:S4-S16. doi: 10.1086/377712
2. Babbott FL, Gordon JE: Modern measles. Am J Med Sci. 1954 Sep;228(3):334-361
3. Liebert UG: Measles virus infections of the central nervous system. Intervirology. 1997;40:176-184. doi: 10.1159/000150544
4. Centers for Disease Control and Prevention (CDC): Measles-United States, 1999. MMWR Morb Mortal Wkly Rep. 2000;49(25):557-560
5. Centers for Disease Control and Prevention (CDC): Increased transmission and outbreaks of Measles-European region. MMWR Morb Mortal Wkly Rep. 2011;60(47):1605-1610
6. Cremer NE, Devlin VL, Riggs JL, Hagens SJ: Anomalous antibody responses in viral infection: specific stimulation or polyclonal activation? J Clin Microbiol. 1984;20:468-472
7. Theel ES, Sorenson M, Rahman C, Granger D, Vaughn A, Breeher L: Performance characteristics of a multiplex flow immunoassay for detection of IgG-Class antibodies to measles, mumps, rubella, and Varicella-Zoster viruses in presumptively immune health care workers. J Clin Microbiol. 2020 Mar 25;58(4):e00136-20. doi: 10.1128
8. National Center for Immunization and Respiratory Diseases, Division of Viral Diseases; Centers for Disease Control and Prevention (CDC). Measles (Rubeola). CDC; Updated November 5, 2020. Accessed October 25, 2022. Available at www.cdc.gov/measles/hcp/index.html
Method Description
Immunoglobulin M:
The presence of IgM-class antibody to measles is determined by an indirect immunofluorescence assay. After removal of IgG by specific immunoglobulin antibody, the serum is incubated with measles antigen, which is adhered to a glass microscope slide. Antibodies, if present, will bind to the antigen forming stable antigen-antibody complexes. If no antibodies are present, the complexes will not be formed, and the serum components will be washed away. Fluorescein-labeled antihuman-IgM antibody is added to the reaction side and binds to IgM antibodies if present. This results in a positive reaction of bright apple-green fluorescence when viewed with a fluorescence microscope.(Package insert: Measles Virus Antigen Substrate Slide. AESKU.BION; 09/2019)
Immunoglobin G:
The BioPlex 2200 Measles IgG assay uses multiplex flow immunoassay technology. Briefly, serum samples are mixed and incubated at 37° C with sample diluent and dyed beads coated with measles antigen. After a wash cycle, antihuman-IgG antibody conjugated to phycoerythrin (PE) is added to the mixture and incubated at 37° C. Excess conjugate is removed in another wash cycle and the beads are resuspended in wash buffer. The bead mixture then passes through a detector that identifies the bead based on dye fluorescence and determines the amount of antibody captured by the antigen based on the fluorescence of the attached PE. Raw data is calculated in relative fluorescence intensity.
Three additional dyed beads, an internal standard bead, a serum verification bead, and a reagent blank bead, are present in each reaction mixture to verify detector response, the addition of serum to the reaction vessel and the absence of significant nonspecific binding in serum.(Package insert: BioPlex 2200 System MMRV IgG. Bio-Rad Laboratories; 02/2019)
Report Available
Same day/1 to 3 daysSpecimen Retention Time
14 daysReject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Heat-inactivated specimen | Reject |
Method Name
ROM: Immunofluorescence Assay (IFA)
ROPG: Multiplex Flow Immunoassay (MFI)
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.Forms
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.